Trial Profile
A multidose, randomized, crossover study to evaluate patient preference for oral vs intravenous Bondronat in patients with metastatic bone disease from breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Feb 2010
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Therapeutic Use
- Acronyms PREFERENCE
- Sponsors Roche
- 16 Jul 2008 Status changed from in progress to completed, from Roche record.
- 20 Jun 2006 New trial record.